1 active not recruiting, 1 recruiting. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Antineoplastic Agents: new trials by email Literature Review of Antineoplastic Agents trials Research Report on Antineoplastic Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) Tovorafenib, Chemotherapeutic Agent - Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma | Phase 3 | Active not recruiting | Day One Biopharmaceuticals, Inc. | 418 | 2023-02-27 | 2026-10-19 |
| Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib Niraparib, Niraparib + TSR-042 (Dostarlimab), Chemotherapy Drugs - Ovarian Carcinosarcoma, Endometrial Carcinosarcoma | Phase 2 / Phase 3 | Recruiting | ARCAGY/ GINECO GROUP | 138 | 2020-07-15 | 2026-09-09 |
ARCAGY/ GINECO GROUP (1) · Day One Biopharmaceuticals, Inc. (1)
France (2) · Italy (2) · Spain (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · Denmark (1) · Egypt (1) · Finland (1) · Germany (1) · Greece (1) · Hungary (1)